Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565052 | 0.96 | HRH3 (0.34) | HRH3 | |
| SCHEMBL24185424 | 0.88 | HRH3 (0.34) | HRH3 | |
| SCHEMBL24185673 | 0.86 | HRH3 (0.33) | HRH3 | |
| SCHEMBL24480641 | 0.84 | — | — | |
| SCHEMBL22565987 | 0.84 | CYP3A4 (0.36) | HRH3 | |
| SCHEMBL22565062 | 0.82 | HRH3 (0.32) | HRH3 | |
| SCHEMBL24480416 | 0.81 | HRH3 (0.34) | HRH3 | |
| SCHEMBL26743369 | 0.81 | — | — | |
| SCHEMBL1753855 | 0.81 | HRH3 (0.38) | HRH3 | |
| SCHEMBL22565063 | 0.81 | OPRL1 (0.34) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | HRH3 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.